News
Summary. Itepekimab's inconsistent phase 3 results represent a setback for Regeneron Pharmaceuticals and Sanofi. The results do not support regulatory submissions and a 3-4 year approval delay ...
Sanofi’s R&D site in Vitry-Sur-Seine, near Paris. Sanofi and Regeneron said that drug candidate Itepekimab didn’t hit the main objective of a second trial.
Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on Dupixent. Read more about why SNY is still a Buy.
A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in one Phase 3 trial.
Regeneron Pharmaceuticals and Sanofi announced that their Phase 3 clinical trial, AERIFY-1, showed a significant 27% reduction in moderate to severe exacerbations of COPD in former smokers treated ...
Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal.
Itepekimab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement and is currently in clinical development programs for CRSwNP (phase 3), non-cystic fibrosis ...
Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies - WHNT News 19
Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in ...
At the time, Houman Ashrafian, Ph.D., Sanofi’s head of R&D, described the COPD readouts as “significant” and told analysts they could potentially lead to itepekimab’s market launch in 2026.
Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab in former smokers who have inadequately controlled chronic obstructive pulmonary ...
Sanofi had touted the drug, itepekimab, as a potential blockbuster candidate and estimated in late 2023 that it could generate annual peak sales of between 2 billion and 5 billion euros ($2.27 ...
Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results